MiNK Therapeutics Past Earnings Performance
Past criteria checks 0/6
MiNK Therapeutics's earnings have been declining at an average annual rate of -6.7%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-6.7%
Earnings growth rate
4.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely
Oct 26
Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?
Jun 28Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?
Mar 18MiNK Therapeutics GAAP EPS of -$0.18
Aug 16MiNK Therapeutics GAAP EPS of -$0.18
Aug 09MiNK Therapeutics A Bargain For Potential Cell Therapies
Jun 23We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely
May 05Revenue & Expenses BreakdownBeta
How MiNK Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -22 | 7 | 15 |
| 30 Sep 23 | 0 | -25 | 7 | 18 |
| 30 Jun 23 | 0 | -26 | 7 | 21 |
| 31 Mar 23 | 0 | -26 | 7 | 22 |
| 31 Dec 22 | 0 | -28 | 8 | 23 |
| 30 Sep 22 | 0 | -26 | 8 | 21 |
| 30 Jun 22 | 0 | -34 | 7 | 18 |
| 31 Mar 22 | 0 | -34 | 6 | 16 |
| 31 Dec 21 | 0 | -30 | 5 | 14 |
| 30 Sep 21 | 0 | -26 | 2 | 11 |
| 30 Jun 21 | 0 | -18 | 2 | 10 |
| 31 Mar 21 | 0 | -16 | 1 | 9 |
| 31 Dec 20 | 0 | -16 | 1 | 10 |
| 31 Dec 19 | 1 | -24 | 4 | 20 |
Quality Earnings: INKT is currently unprofitable.
Growing Profit Margin: INKT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INKT is unprofitable, and losses have increased over the past 5 years at a rate of 6.7% per year.
Accelerating Growth: Unable to compare INKT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INKT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: INKT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.